Last reviewed · How we verify
AGS (Experimental)
AGS is an experimental drug that targets the PD-1/PD-L1 pathway.
AGS is an experimental drug that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | AGS (Experimental) |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AGS works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing the immune response against cancer cells.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
Key clinical trials
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (PHASE1)
- Atorvastatin Therapy on Xanthoma in Alagille Syndrome (PHASE4)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (PHASE2)
- KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (PHASE1, PHASE2)
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome (PHASE3)
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial (PHASE4)
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer (PHASE2)
- A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGS (Experimental) CI brief — competitive landscape report
- AGS (Experimental) updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI